Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial ...

Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy ...

First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Pooled HELIOS-A/HELIOS-B safety included 707 patients (30.3% hereditary; remainder wild-type) with median 33.4 months of ...

Glenis Scadding still remembers one of her first patients for sublingual immunotherapy, forty years later. His hay fever was ...

Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading ...

Semaglutide's patent expiry in India could sharply reduce the cost of popular weight-loss and diabetes injections.

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...